MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer

Phase 2
Recruiting
Conditions
Pancreatic Adenocarcinoma Metastatic
Pancreatic Adenocarcinoma
Interventions
First Posted Date
2021-10-14
Last Posted Date
2024-06-25
Lead Sponsor
Colin D. Weekes, M.D., PhD
Target Recruit Count
70
Registration Number
NCT05077800
Locations
🇺🇸

Univesity of Colorado, Aurora, Colorado, United States

🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇺🇸

University of Washington, Seattle, Washington, United States

Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease

Phase 2
Recruiting
Conditions
Sickle Cell Disease
Diffuse Myocardial Fibrosis
Interventions
First Posted Date
2021-08-19
Last Posted Date
2025-01-29
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
24
Registration Number
NCT05012631
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Effect of Losartan or Eprosartan on Fructose Hyperuricemia

Not Applicable
Completed
Conditions
Uric Acid Concentration, Serum, Quantitative Trait Locus 7
Interventions
First Posted Date
2021-07-08
Last Posted Date
2021-07-08
Lead Sponsor
Medical University of Lodz
Target Recruit Count
16
Registration Number
NCT04954560

Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension

Phase 3
Completed
Conditions
Essential Arterial Hypertension
Interventions
Drug: Losartan/Chlorthalidone in fixed dose
First Posted Date
2021-06-15
Last Posted Date
2025-03-13
Lead Sponsor
Laboratorios Silanes S.A. de C.V.
Target Recruit Count
163
Registration Number
NCT04927299
Locations
🇲🇽

Laboratorio Silanes, S.A. de C.V., Mexico City, Mexico

Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis

Phase 1
Active, not recruiting
Conditions
Osteoarthritis, Knee
Interventions
First Posted Date
2021-03-25
Last Posted Date
2024-04-16
Lead Sponsor
Steadman Philippon Research Institute
Target Recruit Count
100
Registration Number
NCT04815902
Locations
🇺🇸

The Steadman Clinic, Vail, Colorado, United States

Secondhand Tobacco Smoke and Cardiovascular Disease

Phase 4
Recruiting
Conditions
Hypertension
Cardiovascular Diseases
Interventions
Drug: Placebo
First Posted Date
2021-01-20
Last Posted Date
2024-07-12
Lead Sponsor
University of California, San Francisco
Target Recruit Count
100
Registration Number
NCT04715568
Locations
🇺🇸

San Francisco Veterans' Affairs Medical Center, San Francisco, California, United States

Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS

Phase 2
Terminated
Conditions
ARDS
COVID-19
Interventions
First Posted Date
2020-11-25
Last Posted Date
2024-06-24
Lead Sponsor
Assistance Publique Hopitaux De Marseille
Target Recruit Count
78
Registration Number
NCT04643691
Locations
🇫🇷

Assistance Publique Hôpitaux de Marseille, Marseille, France

Losartan for Improved Vascular Endothelial Function After Preeclampsia

Early Phase 1
Recruiting
Conditions
Preeclampsia Postpartum
Interventions
First Posted Date
2020-11-17
Last Posted Date
2024-08-16
Lead Sponsor
Anna Stanhewicz, PhD
Target Recruit Count
20
Registration Number
NCT04632589
Locations
🇺🇸

University of Iowa, Iowa City, Iowa, United States

The Effects of Losartan on Emotion Processing

Not Applicable
Conditions
Healthy
Interventions
Drug: Placebo Oral Tablet
First Posted Date
2020-10-28
Last Posted Date
2020-10-28
Lead Sponsor
University of Electronic Science and Technology of China
Target Recruit Count
90
Registration Number
NCT04606212
Locations
🇨🇳

University of Electronic Science and Technology of China, Chengdu, Sichuan, China

Losartan Effects on Emotion-memory Interaction

Not Applicable
Conditions
Healthy
Interventions
Drug: Placebo Oral Tablet
First Posted Date
2020-10-28
Last Posted Date
2020-10-28
Lead Sponsor
University of Electronic Science and Technology of China
Target Recruit Count
60
Registration Number
NCT04606225
Locations
🇨🇳

University of Electronic Science and Technology of China, Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath